[
  {
    "ts": null,
    "headline": "Kratos Defense (KTOS) Jumps 10.9% as Analyst Hikes Price Target",
    "summary": "Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) is one of the 10 Stocks Leave Wall Street Stunned. Kratos Defense jumped by 10.91 percent on Friday to close at $45.84 apiece following an investment firm’s upgrade of its stock price target. In a market note on Thursday, Truist Securities said it raised its price target for […]",
    "url": "https://finnhub.io/api/news?id=1925825c5640fc95af1fd4f50ae896e6fbb7ec105c1fe1f55e3bd65667b01f61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751120676,
      "headline": "Kratos Defense (KTOS) Jumps 10.9% as Analyst Hikes Price Target",
      "id": 135610868,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) is one of the 10 Stocks Leave Wall Street Stunned. Kratos Defense jumped by 10.91 percent on Friday to close at $45.84 apiece following an investment firm’s upgrade of its stock price target. In a market note on Thursday, Truist Securities said it raised its price target for […]",
      "url": "https://finnhub.io/api/news?id=1925825c5640fc95af1fd4f50ae896e6fbb7ec105c1fe1f55e3bd65667b01f61"
    }
  },
  {
    "ts": null,
    "headline": "Nike price target raised to $85 from $73 at Truist",
    "summary": "Truist raised the firm’s price target on Nike (NKE) to $85 from $73 and keeps a Buy rating on the shares after its Q4 results. The company’s turnaround efforts are yielding more rapid improvements than investors were anticipating as channel inventories are getting cleaned up and with holiday orderbooks rising y/y, the analyst tells investors in a research note. While visibility into a return to sales growth and margin recovery appears meaningfully stronger, the stock is still down 15% from where",
    "url": "https://finnhub.io/api/news?id=d0493d4aa896defd4aff2a5220da472d480a8c20f2a60ea8ba884c8d3cedf7a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751111120,
      "headline": "Nike price target raised to $85 from $73 at Truist",
      "id": 135610144,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Truist raised the firm’s price target on Nike (NKE) to $85 from $73 and keeps a Buy rating on the shares after its Q4 results. The company’s turnaround efforts are yielding more rapid improvements than investors were anticipating as channel inventories are getting cleaned up and with holiday orderbooks rising y/y, the analyst tells investors in a research note. While visibility into a return to sales growth and margin recovery appears meaningfully stronger, the stock is still down 15% from where",
      "url": "https://finnhub.io/api/news?id=d0493d4aa896defd4aff2a5220da472d480a8c20f2a60ea8ba884c8d3cedf7a9"
    }
  },
  {
    "ts": null,
    "headline": "Truist Reiterates Eli Lilly (LLY) Buy Rating on Orforglipron Diabetes Drug Data",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its “Buy” rating on Eli Lilly stock. The firm also maintained the price target of $1,038.00. Truist’s move followed Eli Lilly’s presentation at the American Diabetes Association (ADA) 85th Annual […]",
    "url": "https://finnhub.io/api/news?id=9cd9f9f315e47ffd6de69ae1a5f26cfdc41c6806b5f5b38ec02aa5cff0fadab9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751103675,
      "headline": "Truist Reiterates Eli Lilly (LLY) Buy Rating on Orforglipron Diabetes Drug Data",
      "id": 135610869,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its “Buy” rating on Eli Lilly stock. The firm also maintained the price target of $1,038.00. Truist’s move followed Eli Lilly’s presentation at the American Diabetes Association (ADA) 85th Annual […]",
      "url": "https://finnhub.io/api/news?id=9cd9f9f315e47ffd6de69ae1a5f26cfdc41c6806b5f5b38ec02aa5cff0fadab9"
    }
  }
]